Gastrointestinal oncology
Bold Therapeutics Inc. focuses on advanced solid gastrointestinal tumours, with research activity spanning colorectal cancer, gastric cancer, and broader gastrointestinal malignancies.
- Advanced solid gastrointestinal tumours
- Colorectal cancer
- Gastric cancer
The sponsor’s clinical research in this area reflects a strong therapeutic interest in difficult-to-treat digestive system cancers.
Hepatobiliary cancer
The company also studies cholangiocarcinoma, a bile duct cancer within the broader hepatobiliary oncology field.
- Cholangiocarcinoma
- Bile duct malignancies
- Hepatobiliary cancers
This area adds a focused interest in cancers with limited treatment options and significant unmet medical need.
Pancreatic cancer
Bold Therapeutics includes pancreatic cancer among its therapeutic priorities, extending its oncology portfolio into one of the most aggressive solid tumours.
- Pancreatic cancer
- Solid tumours
- Digestive tract malignancies
Its research activity in this disease area aligns with a broader interest in refractory gastrointestinal cancers.
Combination chemotherapy in oncology
The sponsor’s trial portfolio centers on combination chemotherapy for advanced solid tumours, with attention to treatment response in oncology settings.
- Combination chemotherapy
- Advanced solid tumours
- Treatment response
Its clinical interest is concentrated on systemic cancer therapy for patients with advanced disease.
